her2
Entity, reached from Hormuz.
- Evidence
- 135 documents · 35 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 22 Mar 2026, last seen 9 Oct 2026
- Measured
- 30% of mentions say something specific about it; the rest only name it
- As of
- 11 Oct 2026
Where this comes from
- Fierce Pharma · 2026-10-08 · Pfizer's Tukysa snags first-line approval in HER2+ breast cancer maintenance (opens the source in a new tab)
- Latest News · 2026-10-07 · OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma | OSTX Stock News (opens the source in a new tab)
- medRxiv Oncology · 2026-10-07 · Multimodal Artificial Intelligence Predicts Pathological Response and Prognosis in HER2-Positive Early Breast Cancer Treated with Chemotherapy De-escalation Strategies… (opens the source in a new tab)
- FDA · 2026-10-07 · FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-10-06 · Integrated CDK4/6 inhibitor resistance and primary-metastatic discordance in hormone receptor-positive/HER2-negative metastatic breast cancer: a translatio… (opens the source in a new tab)
- The ASCO Post · 2026-10-02 · Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-09-25 · Small cell transformation during acquired resistance to zongertinib in HER2-mutant non-small cell lung cancer: a case report (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-09-25 · Individualized treatment of HER2-positive breast cancer patients with lung metastasis using a circulating tumor cell drug sensitivity test: a case report (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-09-23 · HER2 amplification as a resistance mechanism to osimertinib and its successful treatment with trastuzumab deruxtecan: a case report (opens the source in a new tab)
- Nature Medicine · 2026-09-22 · Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial (opens the source in a new tab)
1 more on file, counted in the evidence above.
Links from here: not yet read.
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with breast cancer (74 documents)seen together
- co-mentioned with fda (51 documents)seen together
- co-mentioned with colorectal cancer (46 documents)seen together
- co-mentioned with immunotherapy (42 documents)seen together
- co-mentioned with egfr (37 documents)seen together
- co-mentioned with lung cancer (35 documents)seen together
- co-mentioned with china (25 documents)seen together
- co-mentioned with her2-directed (24 documents)seen together
- co-mentioned with ctdna (21 documents)seen together
- co-mentioned with asco (20 documents)seen together